Holen Sie sich die Stockscreener-App
2.29
2.14%
-0.05
Handel nachbörslich:
2.29
Schlusskurs vom Vortag:
$2.34
Offen:
$2.36
24-Stunden-Volumen:
485.33K
Relative Volume:
1.15
Marktkapitalisierung:
$215.58M
Einnahmen:
$3.91M
Nettoeinkommen (Verlust:
$-206.53M
KGV:
-0.9225
EPS:
-2.4825
Netto-Cashflow:
$-167.78M
1W Leistung:
-17.63%
1M Leistung:
+78.91%
6M Leistung:
+152.76%
1J Leistung:
+44.94%
1-Tages-Spanne:
$2.22
$2.50
1-Wochen-Bereich:
$2.00
$2.95
52-Wochen-Spanne:
$0.595
$3.075
I Mab Adr Stock (IMAB) Company Profile
Vergleichen Sie IMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
2.29 | 215.58M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-09 | Eingeleitet | Siebert Williams Shank | Buy |
| 2021-06-02 | Eingeleitet | Daiwa Securities | Buy |
| 2021-03-15 | Eingeleitet | Needham | Buy |
| 2021-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-25 | Eingeleitet | Piper Sandler | Overweight |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-12 | Eingeleitet | China Renaissance | Buy |
| 2020-02-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
I Mab Adr Aktie (IMAB) Neueste Nachrichten
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa
Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX
Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN
I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance
Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net
Willdan Group, Inc.'s (NASDAQ:WLDN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Can This Unstoppable Stock Join Microsoft, Nvidia, Apple, Amazon, Alphabet, Meta Platforms, and Tesla in the $1 Trillion Club? - Yahoo Finance
Graphjet Technology Discloses Notice from Nasdaq - Yahoo Finance
B. Riley Financial granted extension from Nasdaq regarding listing rules - Yahoo Finance
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance
Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance
I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance
I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa
I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com
Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com
I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab names Sean Fu as new CEO - Investing.com
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Seagen acquisition will give Pfizer 'anchor asset' that Wall Street desires: CEO Bourla - Yahoo Finance
How to Use the 50 and 200-Day Moving Averages - Yahoo Finance
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab: Dropping Coverage - Morningstar
Finanzdaten der I Mab Adr-Aktie (IMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):